HUTCHMED Achieves Strong Growth in 2025 Despite Global Headwinds
HUTCHMED, a biopharmaceutical company dedicated to developing innovative cancer therapies, has reported a strong performance in 2025 despite facing global headwinds. According to the company's recent conference call transcript, HUTCHMED achieved significant growth in its ex-China sales and rebounded in China oncology products sales.
Notably, the company's flagship product, FRUZAQLA, recorded a 26% growth in ex-China sales compared to last year, resulting in $366 million in in-market sales. This achievement is all the more impressive given that FRUZAQLA has been rolled out to over 38 countries worldwide.
Additionally, HUTCHMED's China oncology products sales showed a strong rebound in the second half of the year, achieving 21% growth compared to its first half interim results. This demonstrates the company's ability to adapt and respond to changing market conditions.
Furthermore, HUTCHMED's cash position has been strengthened to $1.4 billion, allowing the company to accelerate its global ATTC development and explore potential in-licensing and M&A opportunities. The company is also pursuing business development opportunities with multinational companies.
"We are pleased with our ex-China FRUZAQLA sales, which had 26% growth versus last year, resulting in $366 million in in-market sales," said Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED. "More importantly, FRUZAQLA has rolled out to over 38 countries already."
HUTCHMED's strong financial performance is reflected in its key highlights for 2025. The company recorded $286 million in total oncology revenue, including $71 million in R&D-related upfront and milestone revenues. Net income for the year was $457 million, mainly due to a SHPL divestment gain of $160 million.
"Our R&D expenses for 2025 were $148 million," added Lorenso Chiu, Deputy CFO of HUTCHMED. "Expenses were lower versus 2024 as many of our late-stage trials are in the completion stage, with multiple NDAs now awaiting approvals."
Looking ahead to 2026, HUTCHMED's oncology revenue guidance is expected to be in a range of $330 million-$450 million. This reflects strong solid growth from 2025, driven by China commercial products sales and new indications.
"
